Literature DB >> 29553292

Change gout: how to deal with this "silently-developing killer" in everyday clinical practice.

Carlo Alberto Scirè1,2, Cristina Rossi3, Leonardo Punzi4, Augusto Genderini5, Claudio Borghi6, Walter Grassi7.   

Abstract

BACKGROUND: Despite being regarded as an easily-treatable disease, gout diagnosis and management can be challenging. REVIEW: This review discusses current issues in gout management and proposes some potential solutions. Gout diagnosis should be reached as early as possible and often requires specific tests, such as synovial fluid analysis or imaging techniques that are not available in most centers, leaving healthcare professionals to rely only on clinical presentations and their experience. In addition, gout management requires the evaluation of multiple aspects, such as monitoring of serum uric acid (sUA) level (which should be reduced to <6 mg/dL) to ensure adherence and efficacy of treatment, evaluation of patient's risk profile and comorbidities, and continuous assessments to manage clinical manifestations. An important premise in gout management is non-pharmacological intervention; however, pharmacological urate-lowering therapy is crucial for an optimal control of the disease. Available options include xanthine-oxidase inhibitors (XOI), targeting uric acid overproduction, and uricosuric agents which target the predominant cause of hyperuricemia (under-excretion). Among these, lesinurad is the novel uricosuric agent to be used in combination with XOI in patients with gout not adequately controlled with XOI alone, which can further contribute to the control of hyperuricemia in gout.
CONCLUSIONS: Multidisciplinary management is crucial for the diagnosis and treatment of gout, in order to ensure treatment continuity and improve management. This review, therefore, advises that educational activities for General Practitioners and specialists should be implemented to help raise awareness on gout diagnosis, monitoring, and treatment.

Entities:  

Keywords:  Gout/pathology; gout/diagnosis; gout/drug therapy; hyperuricemia; uricosuric agents; xanthine oxidase/antagonists & inhibitors

Mesh:

Substances:

Year:  2018        PMID: 29553292     DOI: 10.1080/03007995.2018.1454896

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Authors:  Claudio Borghi; Justyna Domienik-Karłowicz; Andrzej Tykarski; Krystyna Widecka; Krzysztof J Filipiak; Miłosz J Jaguszewski; Krzysztof Narkiewicz; Giuseppe Mancia
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 2.737

2.  Correlation of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and mean platelet volume (MPV) with gout activity: A monocentric and retrospective study.

Authors:  Haihua Wu; Hui Zhou; Panfeng Chen
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

3.  Aqueous and Methanol Extracts of Paullinia pinnata (Sapindaceae) Improve Monosodium Urate-Induced Gouty Arthritis in Rat: Analgesic, Anti-Inflammatory, and Antioxidant Effects.

Authors:  Pius Pum Tseuguem; Télesphore Benoît Nguelefack; Basile Ngnanmegne Piégang; Sorelle Mbankou Ngassam
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-05       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.